Physician profile
Wayne H Dunn
NPI 1669472114
$3,498.68
in general payments reported to CMS, 2019-2025
26 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $181 · 2021: $540 · 2022: $635 · 2023: $521 · 2024: $694 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $816.72 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $534.21 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $378.92 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $361.87 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Genentech USA, INC. | $166.84 | 2019-2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $165.49 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $122.08 | 2022-2025 | Precision7, Tryptyr |
| Mallinckrodt Hospital Products INC. | $111.58 | 2022 | |
| Abbvie INC. | $90.66 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $90.32 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $73.85 | 2019-2021 | |
| Horizon Therapeutics Plc | $73.36 | 2021-2023 | Tepezza |
| Astellas Pharma US INC | $66.25 | 2023-2025 | Izervay |
| Oyster Point Pharma, INC. | $52.69 | 2023-2024 | Tyrvaya |
| Rxsight INC | $49.80 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $49.70 | 2019-2024 | |
| Apellis Pharmaceuticals, INC. | $46.95 | 2022-2024 | Syfovre |
| Amgen INC. | $42.23 | 2024-2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $41.64 | 2019-2023 | Acuvue |
| Thea Pharma INC. | $37.58 | 2022-2024 | Iyuzeh |
| Dompe US, INC. | $33.44 | 2024 | Oxervate |
| Ani Pharmaceuticals, INC. | $27.09 | 2025 | Iluvien |
| Kala Pharmaceuticals, INC. | $22.06 | 2019 | |
| Ocular Therapeutix, INC. | $14.89 | 2021 | |
| Genentech, INC. | $14.49 | 2023 | Vabysmo |
| Harrow Eye, LLC | $13.97 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.